EDSA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	3 490.00
Gjennomsnittsvolum	11 753.00
Markedsverdi	14.69M
EPS	$-0.600 ( 2024-02-09 )
Neste inntjeningsdato	( $-0.690 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.230
ATR14	$0.101 (2.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Nijhawan Pardeep	Buy	3 083	Common Share
2024-04-01	Nijhawan Pardeep	Buy	3 253	Common Shares
2024-03-25	Nijhawan Pardeep	Buy	5 000	Common Shares
2024-03-01	Nijhawan Pardeep	Buy	2 765	Common Shares
2024-02-01	Nijhawan Pardeep	Buy	2 978	Common Shares

INSIDER POWER
76.45
Last 96 transactions
Buy: 2 359 109 \| Sell: 304 857

Edesa Biotech Inc Korrelasjon

10 Mest positive korrelasjoner
CTRM	0.95
FSEA	0.947
INPX	0.946
SSBK	0.943
XOS	0.941
NUWE	0.937
SBFG	0.935
FFWM	0.934
SGMO	0.934
MDRX	0.933

10 Mest negative korrelasjoner
RMRM	-0.927
MCAA	-0.925
QQC	-0.925
PLPC	-0.92
BNIX	-0.92
MSDA	-0.915
DSEY	-0.913
ZING	-0.912
ARNA	-0.912
VMGA	-0.911

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Edesa Biotech Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-183 471 (0.00 %)
EPS:	$-0.420

FY	2023
Omsetning:	$0
Bruttogevinst:	$-183 471 (0.00 %)
EPS:	$-0.420

FY	2022
Omsetning:	$0
Bruttogevinst:	$-118 188 (0.00 %)
EPS:	$-1.050

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Edesa Biotech Inc

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Sanntidsoppdatering for Edesa Biotech Inc [EDSA]

Upcoming Earnings Alert